View Financial HealthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsCOVA Acquisition 배당 및 자사주 매입배당 기준 점검 0/6핵심 정보n/a배당 수익률0%자사주 매입 수익률총 주주 수익률0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Dec 21ECARX Holdings, Inc. completed the acquisition of COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction.ECARX Holdings Inc. entered into a letter of intent to acquire COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction on September 21, 2021. ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction for $3.4 billion on May 26, 2022. The transaction values ECARX at $3.82 billion pro forma equity value, or pre-money equity value of $3.4 billion. After the closing of the merger, ECARX’s existing shareholders are expected to own approximately 89% of the pro forma combined company. At the closing, current ECARX shareholders will roll their existing equity holdings into the post-business combination company. Upon completion of the transaction, the combined company expects to be listed on Nasdaq under ticker symbol "ECX". The transaction will require the approval of the shareholders of both ECARX and COVA and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The shareholders of COVA will hold a meeting on December 14, 2022 to approve the transaction. The Boards of Directors of ECARX and COVA have unanimously approved the transaction. As of November 18, 2022, the registration statement has been declared effective by the U.S. Securities and Exchange Commission with respect to the transaction. On December 14, 2022,COVA Acquisition shareholders approved the transaction. The closing of the transaction is expected to occur in the fourth quarter of 2022. Proceeds from the transaction will be used to accelerate technology development and the roll-out of new products, support strategic acquisitions or investments, as well as create further pathways for global growth through its international operations office in London and a product development center in Gothenburg, Sweden. UBS AG Hong Kong Branch and Morgan Stanley Asia Limited acted as joint financial advisors to ECARX. Skadden, Arps, Slate, Meagher & Flom acted as international legal counsel to ECARX. Cantor Fitzgerald & Co. acted as capital markets advisor to COVA Acquisition Corp., and Orrick, Herrington & Sutcliffe LLP acted as its legal counsel. COVA has hired D.F. King & Co., Inc. to assist in the proxy solicitation process. COVA will pay to D.F. King & Co., Inc. a fee of $25,000, plus disbursements. Mark Zimkind of Continental Stock Transfer & Trust Company served as transfer agent to COVA. PriceWaterhouseCoopers Advisory LLC acted as the financial advisor and PricewaterhouseCoopers LLP and Roland Berger LLC acted as the due diligence advisors to COVA. ECARX Holdings, Inc. completed the acquisition of COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction on December 20, 2022.공시 • May 27ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) in a reverse merger transaction for $3.4 billion.ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) in a reverse merger transaction for $3.4 billion on May 26, 2022. The transaction values ECARX at $3.82 billion pro forma equity value, or pre-money equity value of $3.4 billion. After the closing of the merger, ECARX’s existing shareholders are expected to own approximately 89% of the pro forma combined company, Upon completion of the transaction expects to be listed on Nasdaq under ticker symbol "ECX". The transaction will require the approval of the shareholders of both ECARX and COVA and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The Boards of Directors of ECARX and COVA have unanimously approved the transaction. The closing of the transaction is expected to occur in the fourth quarter of 2022. Proceeds from the transaction will be used to accelerate technology development and the roll-out of new products, support strategic acquisitions or investments, as well as create further pathways for global growth through its international operations office in London and a product development center in Gothenburg, Sweden. UBS AG Hong Kong Branch and Morgan Stanley Asia Limited acted as joint financial advisors to ECARX. Skadden, Arps, Slate, Meagher & Flom acted as international legal counsel to ECARX. Cantor Fitzgerald & Co. acted as capital markets advisor to COVA Acquisition Corp., and Orrick, Herrington & Sutcliffe LLP acted as its legal counsel.공시 • Apr 09Cova Acquisition Talks with Tiket.Com Reportedly EndedTiket.com has ended talks to come public through a merger with special purpose acquisition company COVA Acquisition Corp., according to Bloomberg's Gillian Tan, Manuel Baigorri, Fathiya Dahrul and Elffie Chew, citing people familiar with the matter. Tiket is now considering a merger with e-commerce platform Blibli, formerly known as PT Global Digital Niaga, instead, the report said.공시 • Jun 03COVA Acquisition Corp Receives Expected Notice from Nasdaq Regarding Delayed Form 10-QOn May 28, 2021, COVA Acquisition Corp. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021 (the “Q1 2021 Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the SEC. The Notice has no immediate impact on the listing or trading of the Company’s securities on the Nasdaq Capital Market. As previously reported in the Form 12b-25 filed with the SEC on May 17, 2021, the Company was unable to file the First Quarter 2021 Form 10-Q by the prescribed due date of May 17, 2021 without unreasonable effort and expense. The Company was unable to file the First Quarter 2021 Form 10-Q by the extension date of May 24, 2021 but subsequently filed the First Quarter 2021 Form 10-Q with the SEC on June 1, 2021. As a result of such filing, the Company expects to regain compliance with the Nasdaq Listing Rule.공시 • May 18COVA Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, COVA Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 COVA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: COVA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장COVA Acquisition 배당 수익률 vs 시장COVA의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (COVA)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Capital Markets)2.0%분석가 예측 (COVA) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 COVA 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 COVA 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 COVA 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: COVA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/12/21 16:18종가2022/12/20 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스COVA Acquisition Corp.는 0명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Dec 21ECARX Holdings, Inc. completed the acquisition of COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction.ECARX Holdings Inc. entered into a letter of intent to acquire COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction on September 21, 2021. ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction for $3.4 billion on May 26, 2022. The transaction values ECARX at $3.82 billion pro forma equity value, or pre-money equity value of $3.4 billion. After the closing of the merger, ECARX’s existing shareholders are expected to own approximately 89% of the pro forma combined company. At the closing, current ECARX shareholders will roll their existing equity holdings into the post-business combination company. Upon completion of the transaction, the combined company expects to be listed on Nasdaq under ticker symbol "ECX". The transaction will require the approval of the shareholders of both ECARX and COVA and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The shareholders of COVA will hold a meeting on December 14, 2022 to approve the transaction. The Boards of Directors of ECARX and COVA have unanimously approved the transaction. As of November 18, 2022, the registration statement has been declared effective by the U.S. Securities and Exchange Commission with respect to the transaction. On December 14, 2022,COVA Acquisition shareholders approved the transaction. The closing of the transaction is expected to occur in the fourth quarter of 2022. Proceeds from the transaction will be used to accelerate technology development and the roll-out of new products, support strategic acquisitions or investments, as well as create further pathways for global growth through its international operations office in London and a product development center in Gothenburg, Sweden. UBS AG Hong Kong Branch and Morgan Stanley Asia Limited acted as joint financial advisors to ECARX. Skadden, Arps, Slate, Meagher & Flom acted as international legal counsel to ECARX. Cantor Fitzgerald & Co. acted as capital markets advisor to COVA Acquisition Corp., and Orrick, Herrington & Sutcliffe LLP acted as its legal counsel. COVA has hired D.F. King & Co., Inc. to assist in the proxy solicitation process. COVA will pay to D.F. King & Co., Inc. a fee of $25,000, plus disbursements. Mark Zimkind of Continental Stock Transfer & Trust Company served as transfer agent to COVA. PriceWaterhouseCoopers Advisory LLC acted as the financial advisor and PricewaterhouseCoopers LLP and Roland Berger LLC acted as the due diligence advisors to COVA. ECARX Holdings, Inc. completed the acquisition of COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction on December 20, 2022.
공시 • May 27ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) in a reverse merger transaction for $3.4 billion.ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) in a reverse merger transaction for $3.4 billion on May 26, 2022. The transaction values ECARX at $3.82 billion pro forma equity value, or pre-money equity value of $3.4 billion. After the closing of the merger, ECARX’s existing shareholders are expected to own approximately 89% of the pro forma combined company, Upon completion of the transaction expects to be listed on Nasdaq under ticker symbol "ECX". The transaction will require the approval of the shareholders of both ECARX and COVA and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The Boards of Directors of ECARX and COVA have unanimously approved the transaction. The closing of the transaction is expected to occur in the fourth quarter of 2022. Proceeds from the transaction will be used to accelerate technology development and the roll-out of new products, support strategic acquisitions or investments, as well as create further pathways for global growth through its international operations office in London and a product development center in Gothenburg, Sweden. UBS AG Hong Kong Branch and Morgan Stanley Asia Limited acted as joint financial advisors to ECARX. Skadden, Arps, Slate, Meagher & Flom acted as international legal counsel to ECARX. Cantor Fitzgerald & Co. acted as capital markets advisor to COVA Acquisition Corp., and Orrick, Herrington & Sutcliffe LLP acted as its legal counsel.
공시 • Apr 09Cova Acquisition Talks with Tiket.Com Reportedly EndedTiket.com has ended talks to come public through a merger with special purpose acquisition company COVA Acquisition Corp., according to Bloomberg's Gillian Tan, Manuel Baigorri, Fathiya Dahrul and Elffie Chew, citing people familiar with the matter. Tiket is now considering a merger with e-commerce platform Blibli, formerly known as PT Global Digital Niaga, instead, the report said.
공시 • Jun 03COVA Acquisition Corp Receives Expected Notice from Nasdaq Regarding Delayed Form 10-QOn May 28, 2021, COVA Acquisition Corp. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021 (the “Q1 2021 Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the SEC. The Notice has no immediate impact on the listing or trading of the Company’s securities on the Nasdaq Capital Market. As previously reported in the Form 12b-25 filed with the SEC on May 17, 2021, the Company was unable to file the First Quarter 2021 Form 10-Q by the prescribed due date of May 17, 2021 without unreasonable effort and expense. The Company was unable to file the First Quarter 2021 Form 10-Q by the extension date of May 24, 2021 but subsequently filed the First Quarter 2021 Form 10-Q with the SEC on June 1, 2021. As a result of such filing, the Company expects to regain compliance with the Nasdaq Listing Rule.
공시 • May 18COVA Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, COVA Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.